KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression
Clinical and Translational Medicine · 2023
DOI: 10.1002/ctm2.1452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Wenyun Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Department of Liver Surgery, Renji-Med-X Clinical Stem Cell Research Center, RenJi Hospital, Sch…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Background
Hepatocellular carcinoma (HCC) is one of the major causes of death from cancer and has a very poor prognosis with few effective therapeutic options. Despite the approval of lenvatinib for the treatment of patients suffering from advanced HCC, only a small number of patients can benefit from this targeted therapy.
Methods
Diethylnitrosamine (DEN)‐CCL4 mouse liver tumour and the xenograft tumour models were used to evaluate the function of KDM6A in HCC progression. The xenograft tumour model and HCC cell lines were used to evaluate the role of KDM6A in HCC drug sensitivity to lenvatinib. RNA‐seq and ChIP assays were conducted for mechanical investigation.
Results
We revealed that KDM6A exhibited a significant upregulation in HCC tissues and was associated with an unfavourable prognosis. We further demonstrated that KDM6A knockdown remarkably suppressed HCC cell proliferation and migration in vitro. Moreover, hepatic Kdm6a loss also inhibited liver tumourigenesis in a mouse liver tumour model. Mechanistically, KDM6A loss downregulated the FGFR4 expression to suppress the PI3K–AKT–mTOR signalling pathway, leading to a glucose and lipid metabolism re‐programming in HCC. KDM6A and FGFR4 levels were positively correlated in HCC specimens and mouse liver tumour tissues. Notably, KDM6A knockdown significantly inhibited the efficacy of lenvatinib therapy in HCC cells in vitro and in vivo.
Conclusions
Our findings revealed that KDM6A promoted HCC progression by activating FGFR4 expression and may be an essential molecule for influencing the efficacy of lenvatinib in HCC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Department of Liver Surgery, Renji-Med-X Clinical Stem Cell Research Center, RenJi Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, P. R. China.
- School of Biomedical Engineering & Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, P. R. China.
- Shanghai Engineering Research Center of Transplantation and Immonology, Shanghai Institute of Transplantation, Shanghai, P. R. China.
ORCID-Profile: Yanfeng Liu
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Guo, W., Li, S., Qian, Y., Li, L., Wang, F., Tong, Y., Li, Q., Zhu, Z., Gao, W. Q., & Liu, Y. (2023). KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1452
Vancouver
Guo W, Li S, Qian Y, Li L, Wang F, Tong Y, et al. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1452
BibTeX
@article{Guo2023,
author = {Guo, Wenyun and Li, Songling and Qian, Yifei and Li, Linfeng and Wang, Fan and Tong, Yu and Li, Qianyu and Zhu, Zijun and Gao, Wei-Qiang and Liu, Yanfeng},
title = {KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression},
journal = {Clinical and Translational Medicine},
year = {2023},
doi = {10.1002/ctm2.1452}
}
EUVIMED